explore -WSS

explore

author：fashion 2025-09-30 16:29:34 - browse：1

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

entertainment

focus

WSS

U.K. decision on ALS drug has neurologists, advocates up in arms

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Overprescribed: High cost isn't America's only drug problem

Health AI: on the border between health care and tech

Timeline: How the deadly wildfires took over Maui day by day

knowledge

explore

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Young boy dies in trial for Pfizer Duchenne gene therapy

Continuity nursing helped my family in our darkest PICU moments

Trial using CRISPR to edit HIV out of cells disappoints

In Memoriam: Notable people who died in 2023

Bird flu researchers hone in on Finland’s mink farms

As demand for Covid shots wanes, Moderna seeks its next success

Bird flu in dairy cattle: New measures to control spread to humans

How to save PrEP access — and even expand it

Megan Rapinoe shares emotional post following US Women's World Cup exit

focus

Oral obesity drug from Viking Therapeutics hits key early target

Mark Cuban is blaming the wrong people for high drug costs

Patients, digital health players weigh in on FTC's data privacy plan

Montana youths win climate lawsuit against state for promoting fossil fuels

Researchers test human milk's ability to repair gut microbiome

Young boy dies in trial for Pfizer Duchenne gene therapy

entertainment

entertainment

focus

focus